UroGen Pharma

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell UroGen Pharma and other ETFs, options, and stocks.

About URGN

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology.

CEO

Elizabeth Barrett

CEOElizabeth Barrett

Employees

291

Employees291

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

2004

Founded2004

Employees

291

Employees291

URGN Key Statistics

Market cap

996.53M

Market cap996.53M

Price-Earnings ratio

-6.37

Price-Earnings ratio-6.37

Dividend yield

—

Dividend yield—

Average volume

1.14M

Average volume1.14M

High today

$20.82

High today$20.82

Low today

$18.68

Low today$18.68

Open price

$19.10

Open price$19.10

Volume

1.23M

Volume1.23M

52 Week high

$30.00

52 Week high$30.00

52 Week low

$3.42

52 Week low$3.42

Stock Snapshot

With a market cap of 996.53M, UroGen Pharma(URGN) trades at $20.58. The stock has a price-to-earnings ratio of -6.37.

On 2026-03-08, UroGen Pharma(URGN) stock traded between a low of $18.68 and a high of $20.82. Shares are currently priced at $20.58, which is +10.2% above the low and -1.2% below the high.

The UroGen Pharma(URGN)'s current trading volume is 1.23M, compared to an average daily volume of 1.14M.

During the past year, UroGen Pharma(URGN) stock moved between $3.42 at its lowest and $30.00 at its peak.

URGN News

Simply Wall St 3d

Assessing UroGen Pharma Valuation After Recent Share Price Volatility

Advertisement Why UroGen Pharma (URGN) is on investors’ radar today UroGen Pharma (URGN) has drawn fresh attention after recent trading saw the stock close at...

TipRanks 6d

Trade Tensions Put UroGen Pharma’s Margins, Pipeline and Growth at Risk

Urogen Pharma (URGN) has disclosed a new risk, in the Capital Markets category. UroGen Pharma’s reliance on a global supply chain for Jelmyto, Zusduri and pipe...

TipRanks 6d

UroGen Pharma Secures New $250 Million Term Loan

Urogen Pharma ( (URGN) ) has shared an announcement. On February 26, 2026, UroGen Pharma Ltd. and its U.S. subsidiary entered into a new loan agreement with Bi...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More URGN News

TipRanks 6d

UroGen Pharma announces refinanced term loan agreement with Pharmakon

UroGen Pharma (URGN) entered into an agreement with funds managed by Pharmakon Advisors to revise the terms of its loan agreement entered into in March 2024. On...

People also own

Based on the portfolios of people who own URGN. This list is generated using Robinhood data, and it’s not a recommendation.

Palantir Technologies

Viking Therapeutics

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.